Keros Therapeutics presents a speculative, event-driven equity story in which the balance sheet remains well-capitalized at $257.6M of cash against just $25.3M of total liabilities, but the underlying operating model has yet to demonstrate recurring economics—revenue collapsed from a $211.2M single-quarter print in…
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.70+172.9% vs -$0.96 | $40M+171.0% vs $15M |
Q3 2026 Aug 3, 2026 | -$1.45-8.2% vs -$1.34 | — vs $807,143 |
Q2 2026 May 14, 2026 | -$1.21-31.5% vs -$0.92 | $367,000-81.0% vs $2M |
Q2 2026 Mar 4, 2026 | -$0.86-75.5% vs -$0.49 | $385,000-89.5% vs $4M |
Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of a loss of $0.96 per share. This compares to a loss of $0.18 per share a year ago.
Keros Therapeutics NASDAQ: KROS is repositioning its pipeline around rinvatercept, a skeletal-muscle regeneration candidate being developed for neuromuscular diseases, while its partnered program eleriscept advances through late-stage development under Takeda, Chief Executive Officer Jasbir Seehra said during a fireside chat hosted by Chardan.
Keros Therapeutics (NASDAQ: KROS - Get Free Report) and Upstream Bio (NASDAQ: UPB - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation. Volatility and Risk Keros Therapeutics has a
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
Benchmark KROS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Keros Therapeutics, Inc. (KROS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.36 | $299.5M | 4.07 | 6774.96% | -151.43% | -21.85% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $300.88 | $8.87B | 41.21 | 33.94% | 47.91% | 17.02% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $16.33 | $13.03B | -15.65 | — | — | -158.78% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — |
Keros Therapeutics, Inc. (KROS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Keros Therapeutics, Inc. (KROS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Aug 3, 2026·SEC
Jul 30, 2026·SEC
Get notified when KROS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Keros Therapeutics, Inc. (KROS) stock FAQ — growth, dividends, profitability & financials explained
Keros Therapeutics, Inc. (KROS) reported $40.8M in revenue over the trailing twelve months. Revenue was $244.1M in fiscal year 2025. That is 2341% more than the $10.0M of fiscal year 2018.
Keros Therapeutics, Inc. (KROS) revenue fell by 83.5% over the trailing twelve months, compared with the twelve months before.
No. Keros Therapeutics, Inc. (KROS) reported a net loss of $61.7M over the trailing twelve months.
Keros Therapeutics, Inc. (KROS) had a return on equity (ROE) of -21.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Keros Therapeutics, Inc. (KROS) had negative free cash flow of $48.3M over the trailing twelve months.
